TAK-981: A First in Class SUMO Inhibitor in Phase 1 Trials That Promotes Dendritic Cell Activation, Antigen-Presentation, and T Cell Priming
CANCER RESEARCH（2019）
Key words
SUMOylation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined